Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 9/20 | 0.84 |
| ▸ | RXRB | P28702 | 9/20 | 0.84 |
| ▸ | RXRG | P48443 | 9/20 | 0.84 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.79 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.79 |
| ▸ | CCKAR | P32238 | 9/20 | 0.68 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9519465 | 0.91 | PTGS2 (0.79) | RXRARXRBRXRGALOX5PTGS2 | |
| SCHEMBL9522066 | 0.90 | PTGS2 (0.77) | RXRARXRBRXRGALOX5PTGS2 | |
| SCHEMBL9521167 | 0.90 | PTGS2 (0.77) | RXRARXRBRXRGALOX5PTGS2 | |
| SCHEMBL9695677 | 0.90 | RXRA (0.74) | RXRARXRBRXRGALOX5PTGS2 | |
| SCHEMBL9519737 | 0.90 | ALOX5 (0.71) | RXRARXRBRXRGALOX5PTGS2 | |
| SCHEMBL9520164 | 0.89 | PTGS2 (0.76) | RXRARXRBRXRGALOX5PTGS2 | |
| Water SCHEMBL10551403 | 0.88 | PTGS2 (0.74) | RXRARXRBRXRGALOX5PTGS2 | |
| SCHEMBL9519230 | 0.88 | PTGS2 (0.74) | RXRARXRBRXRGALOX5PTGS2 | |
| Tepoxalin SCHEMBL75441 | 0.88 | PTGS2 (1.00) | RXRARXRBRXRGALOX5PTGS2 | |
| SCHEMBL5382607 | 0.87 | PTGS2 (0.76) | RXRARXRBRXRGALOX5PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3877056-B1 | TEPOXALIN TARGETING OF ABCB1 OVEREXPRESSING CANCERS | BROAD INST INC (US) | 2025-07-02 | — | — | EP | claimed |
| US-20220065864-A1 | TEPOXALIN TARGETING OF ABCB1 OVEREXPRESSING CANCERS | THE BROAD INSTITUTE, INC. (US) | 2022-03-03 | — | — | US | claimed |
| US-5164381-A | Cardiovascular, antiinflammatory | ORTHO PHARMACEUTICAL CORPORATION (US) | 1992-11-17 | — | — | US | claimed |
| EP-3877056-B1 | TEPOXALIN TARGETING OF ABCB1 OVEREXPRESSING CANCERS | BROAD INST INC (US) | 2025-07-02 | — | — | EP | disclosed |
| US-12313632-B2 | Tepoxalin targeting of ABCB1 overexpressing cancers | THE BROAD INSTITUTE, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20220065864-A1 | TEPOXALIN TARGETING OF ABCB1 OVEREXPRESSING CANCERS | THE BROAD INSTITUTE, INC. (US) | 2022-03-03 | — | — | US | disclosed |
| US-7247745-B2 | Process for preparing 1,5-diaryl-3-substituted pyrazoles | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247745-B2 | Process for preparing 1,5-diaryl-3-substituted pyrazoles | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247745-B2 | Process for preparing 1,5-diaryl-3-substituted pyrazoles | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1413575-B1 | Process for preparing derivatives of ¬(1,5-diaryl)pyrazol-3-yl|propanoic acid | ORTHO MCNEIL PHARM INC (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20060004208-A1 | Process for preparing 1,5-diaryl-3-substituted pyrazoles | ABDEL-MAGID AHMED F | 2006-01-05 | — | — | US | disclosed |
| EP-1144382-A3 | PROCESS FOR PREPARING 1,5-DIARYL-3-SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| US-6384233-B1 | PHENYL KETONE DERIVATIVE REACTED WITH SUCCINIC ANHYDRIDE ANDPOTASSIUM T-BUTOXIDE, DIKETONE PRODUCT REACTED WITH HYDRAZINE DERIVATIVE TO CAUSE CYCLIZATION, ESTERIFICATION WITH ETHANOL AND REACTING WITH N-METHYLHYDROXYLAMINE HYDROCHLORIDE | ABDEL-MAGID AHMED F (US) | 2002-05-07 | — | — | US | disclosed |
| US-20020032336-A1 | Process for preparing 1,5-diaryl-3-substituted pyrazoles | ABDEL-MAGID AHMED F (US) | 2002-03-14 | — | — | US | disclosed |
| EP-1144382-A2 | PROCESS FOR PREPARING 1,5-DIARYL-3-SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001009102-A2 | PROCESS FOR PREPARING 1,5-DIARYL-3-SUBSTITUTED PYRAZOLES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| EP-0248594-B1 | Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same | ORTHO PHARMA CORP (US) | 1993-11-24 | — | — | EP | disclosed |
| US-5164381-A | Cardiovascular, antiinflammatory | ORTHO PHARMACEUTICAL CORPORATION (US) | 1992-11-17 | — | — | US | disclosed |
| US-4826868-A | 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0248594-A2 | Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004208-A1 | Process for preparing 1,5-diaryl-3-substituted pyrazoles | ADH5, ADH1C, ADH1A | RXRA 3508/4885RXRB 3479/4885RXRG 3436/4885 |
| US-20020032336-A1 | Process for preparing 1,5-diaryl-3-substituted pyrazoles | ADH5, ADH1C, ADH1A | RXRA 3635/4885RXRB 3558/4885RXRG 3530/4885 |
| US-12313632-B2 | Tepoxalin targeting of ABCB1 overexpressing cancers | ABCC1, ABCB1, ABCC8 | RXRA 2529/4885RXRB 1762/4885RXRG 2051/4885 |
| US-20220065864-A1 | TEPOXALIN TARGETING OF ABCB1 OVEREXPRESSING CANCERS | ABCC1, ABCB1, ABCC8 | RXRA 2529/4885RXRB 1762/4885RXRG 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.